Home » GlaxoSmithKline Boosts Arthritis-Drugs Deal With Galapagos to $291 Million
GlaxoSmithKline Boosts Arthritis-Drugs Deal With Galapagos to $291 Million
GlaxoSmithKline, the U.K.-based pharma giant with North American
headquarters in Research Triangle Park, has extended its agreement with Belgian-drug maker Galapagos to develop new arthritis drugs.
Triangle Business Journal
Triangle Business Journal
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May